Views & Analysis Words matter during a heart attack Recent research suggests that the ways in which men and women describe heart attack symptoms differently can affect diagnosis in urgent situations.
News Novartis' canakinumab cuts risk for heart attack survivors Novartis to discuss canakinumab results with regulators.
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face